400 - The MEK1/2 inhibitor selumetinib (AZD6244; ARRY-142886) appears as an efficient targeted therapy when used in an adjuvant setting in patient-derived xenografts of uveal melanoma
| Autor: | Diallo, B., Massonnet, G., El-Botty, R., Raymondie, C., Howes, C., Wilson, J., Smith, A., Roman-Roman, S., Smith, P., Davies, E., Decaudin, D., Némati, F. |
|---|---|
| Zdroj: | In European Journal of Cancer December 2016 69 Supplement 1:S132-S132 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect